21.71
-0.28 (-1.27%)
| 前收盘价格 | 21.99 |
| 收盘价格 | 21.63 |
| 成交量 | 109,173 |
| 平均成交量 (3个月) | 645,979 |
| 市值 | 1,398,382,336 |
| 价格/销量 (P/S) | 19.79 |
| 股市价格/股市净资产 (P/B) | 3.43 |
| 52周波幅 | |
| 利润日期 | 14 Oct 2024 - 18 Oct 2024 |
| 营业利益率 (TTM) | -433.83% |
| 稀释每股收益 (EPS TTM) | -2.90 |
| 季度收入增长率 (YOY) | -31.80% |
| 总债务/股东权益 (D/E MRQ) | 7.20% |
| 流动比率 (MRQ) | 5.28 |
| 营业现金流 (OCF TTM) | -97.14 M |
| 杠杆自由现金流 (LFCF TTM) | -56.77 M |
| 资产报酬率 (ROA TTM) | -29.46% |
| 股东权益报酬率 (ROE TTM) | -57.96% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Nurix Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.80 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.45% |
| 机构持股比例 | 97.78% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 35.00 (BTIG, 61.22%) | 购买 |
| 35.00 (HC Wainwright & Co., 61.22%) | 购买 | |
| 35.00 (BMO Capital, 61.22%) | 购买 | |
| 35.00 (UBS, 61.22%) | 购买 | |
| 中 | 35.00 (61.22%) | |
| 低 | 29.00 (Needham, 33.58%) | 购买 |
| 平均值 | 33.80 (55.69%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 22.40 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2024 | 35.00 (61.22%) | 购买 | 21.31 |
| 21 Oct 2024 | 30.00 (38.19%) | 购买 | 25.48 | |
| BTIG | 10 Dec 2024 | 35.00 (61.22%) | 购买 | 22.06 |
| Needham | 10 Dec 2024 | 29.00 (33.58%) | 购买 | 22.06 |
| 06 Nov 2024 | 29.00 (33.58%) | 购买 | 27.00 | |
| BMO Capital | 06 Dec 2024 | 35.00 (61.22%) | 购买 | 21.37 |
| UBS | 24 Oct 2024 | 35.00 (61.22%) | 购买 | 25.22 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| RING CHRISTINE | - | 19.51 | -5,760 | -112,378 |
| 累积净数量 | -5,760 | |||
| 累积净值 ($) | -112,378 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 19.51 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| RING CHRISTINE | 职员 | 02 Jan 2025 | 自动卖出 (-) | 5,760 | 19.51 | 112,378 |
| RING CHRISTINE | 职员 | 02 Jan 2025 | 执行期权 | 5,760 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合